ASCO22: Breast cancer research by Chris Labaki, MD
Dana-Farber's Chris Labaki, MD details how Real-World Progression-Free Survival and Time to Next Line of Therapy may be useful intermediate endpoints for survival in patients with advanced breast cancer.
target survival endpoints are of high importance because they play a role in the approval of new drugs by the FDA. And also in the implementation of new oncological guidelines. We start to look at two endpoints of clinical interest which are the real world progression free survival and time to the next line of therapy in patients with metastatic breast cancer. And this work was conducted in collaboration with the iron core network of Roche and Genentech. With the data provided from the Flat iron database our cohort and encompasses around 10,000 patients with metastatic breast cancer. With data about overall survival rate, work PFS and time to the next line of therapy or D. TNT. We looked at the correlation between each circuit and point and overall survival, which is considered as the gold standard using dedicated popular models and found a meaningful correlation between radio PFS and overall survival, also between T. T. N. T. And overall survival. This data and the results obtained are highly encouraging because they would help to implement um circuit and points which are more easily acquired in clinical practice um and more easily achieved in clinical practice in the treatment and in the evaluation of patients with metastatic breast cancer.
